Idelalisib-related pneumonitis
E Haustraete, J Obert, S Diab, S Abbes… - European …, 2016 - Eur Respiratory Soc
Idelalisib (Zydelig; Gilead Sciences Inc., Foster City, CA, USA) has recently been approved
in combination with rituximab for the treatment of refractory chronic lymphocytic leukaemia (…
in combination with rituximab for the treatment of refractory chronic lymphocytic leukaemia (…
[HTML][HTML] Observational study of QuantiFERON®-TB gold in-tube assay in tuberculosis contacts in a low incidence area
E Bergot, E Haustraete, B Malbruny, R Magnier… - 2012 - journals.plos.org
Background QuantiFERON®-TB Gold in-Tube (QFT) assay is a recently developed test to
assess latent tuberculosis infection in contagious tuberculosis (TB) contact subjects. To assess …
assess latent tuberculosis infection in contagious tuberculosis (TB) contact subjects. To assess …
[HTML][HTML] Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment …
A Lievre, A Turpin, I Ray-Coquard, K Le Malicot… - European Journal of …, 2020 - Elsevier
Background Cancer patients are thought to have an increased risk of developing severe
Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, …
Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, …
[CITATION][C] Intérêt du QuantiFERON TB Gold in-tube® dans les enquêtes autour d'un cas de tuberculose dans une région de faible incidence
E Haustraete - 2010